GensiaSicor

Gensia Sicor was a prominent specialty pharmaceutical company that focused on the development and manufacture of generic injectable drugs and active pharmaceutical ingredients (APIs). Formed in 1997 through the merger of the American biotechnology firm Gensia Inc. and the Italian API manufacturer Sicor S.p.A., the company became a leader in the hospital-based injectable market. Its product portfolio primarily addressed critical needs in oncology, anesthesiology, and anti-infective therapy, featuring complex formulations like generic propofol. The company operated high-capacity manufacturing facilities in the United States, Italy, and Mexico, serving a global customer base. In 2004, Teva Pharmaceutical Industries acquired Gensia Sicor for approximately $3.4 billion to significantly expand its presence in the high-growth injectable medicine sector.